Selecting Prescription Drugs For Affordability Review, Part 1

Washington State
Health Care Authority

Overview

Brief overview of RCW 70.405.040: Affordability Reviews

Data Measures For Affordability Review Selection

Discussion Points

Next steps and Q&A

Overview

Identify eligible prescription drugs for affordability review

Select prescription drugs for affordability review

Conduct affordability review

Determine unaffordability

Focus of this presentation

Brief Overview of RCW 70.405.040: Affordability Reviews

Washington State
Health Care Authority

Deciding Whether To Conduct A Review

- The Board shall consider:
  - The class of the prescription drug and whether any therapeutically equivalent prescription drugs are available for sale;
  - Input from relevant advisory groups established pursuant to RCW 70.405.020; and
  - The average patient's out-of-pocket cost for the drug.
- Board can choose up to 24 drugs per year

Data Measures For Affordability Review Selection

Washington State
Health Care Authority

Deciding Whether To Conduct A Review

The Board shall consider:

Drug class, price, and availability of therapeutic alternatives

Average patient out-of-pocket costs

Input from relevant advisory groups

\+ ???

Choosing Drugs For Affordability Review

Conducting Affordability Review

Drug class, price, therapeutic alternatives

Average patient out-of-pocket costs and/or other cost sharing

Input from advisory groups as per RCW 70.405.020

Factors contributing to the price paid for the prescription drug

Effect of the price on consumers' access to the drug in the state

Orphan drug status

Dollar value and accessibility of patient assistance programs

Input from patients and subject matter experts

Impact of PBM policies on the price consumers pay for the drug

Any other information the drug manufacturer or other relevant entity chooses to provide

Any other relevant factors as determined by the board

What Data Sources Are Available?

Washington State All Payers Claim Database (APCD)

- Prescription drug utilization
- Patient out-of-pocket costs

Manufacturer data

- Pricing data
- Profit data
- Rebate data

PBM data

- Prescription drug utilization
- Rebate data

First Databank

- Pricing data
- Prescription drug information (i.e. therapeutic alternatives)

Medi-Span

- Pricing data
- Prescription drug information (i.e. therapeutic alternatives)

Discussion Points

|	
💊	What is your definition of "affordable" when it comes to prescription drugs?
💵	Who should prescription drugs be affordable for?
🎯	What is the most important goal you want affordability review to address?
👨‍⚕️	Is there a data measure that is more important than others when selecting prescription drugs for review?
📈	Are there any data measures you are interested in looking at that weren't mentioned?
⚖️	Do you have any strong interest or preference for any specific data measures?

Next Steps

Dive into deeper detail on potential data measures for selecting prescription drugs for affordability review

Choose data measures to be used for selecting prescription drugs for affordability review

Develop methodology used for selecting prescription drugs for affordability review

Create dashboard of eligible prescription drugs and chosen data measures

Discussion and Questions

Washington State
Health Care Authority